Document is current
Any future updates will be listed below
-
Authors
,
Derks-Smeets, Inge A. P.
Schrijver, Lieske H.
de Die-Smulders, Christine E. M.
Tjan-Heijnen, Vivianne C. G.
van Golde, Ron J. T.
Smits, Luc J.
Caanen, Beppy
van Asperen, Christi J.
Ausems, Margreet
Collée, Margriet
van Engelen, Klaartje
Kets, C. Marleen
van der Kolk, Lizet
Oosterwijk, Jan C.
van Os, Theo A. M.
Rookus, Matti A.
van Leeuwen, Flora E.
Gómez García, Encarna B.
- License Information
-
More Information
Article History
Received: 6 November 2017
Revised: 23 April 2018
Accepted: 14 May 2018
First Online: 25 June 2018
Competing interests
: The authors declare no competing interests.
: This study was financially supported by a personal grant for I. Derks-Smeets, kindly provided by the Dutch Cancer Society (grant number 2011-5249). The HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the Netherlands Organisation of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187.WO76, the BBMRI grant NWO 184.021.007/CP46 and the Transcan grant JTC 2012 Cancer 12-054.
: The HEBON study was approved by the medical ethics committees of all participating Dutch University Medical Centres or Family Cancer Clinics. All HEBON participants gave their informed consent for linkage with the nationwide cancer and pathology registries. The PGD programme has been approved by the Institutional Review Board of Maastricht University Medical Centre. All patients undergoing PGD gave their written informed consent for this treatment and use of their medical data for scientific research.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
